Sakar Healthcare Ltd Q3 FY26 Earnings Analysis

- Oncology plant full capacity utilization can generate revenues of around INR 1,000 crores (Page 15). - Aspiration to achieve INR 1,000 crores top line in oncology by FY 2030 (Page 16). - Current exports and contract agreements indicate potential of more than INR 450 crores from oncology products (Page 7). - Targeted revenue for FY 2026 is INR 280 crores, with half-year actuals around INR 100 crores and expected ramp-up in H2 (Pages 8 and 16). - 11 marketing authorizations approved; commercialization to boost exports primarily in Q4 FY 2026 (Page 8). - Growth supported by new contracts with Indian multinationals and technology transfers ongoing (Page 8). - Working capital will increase proportionally with sales growth; no major new CapEx expected post current expansions (Page 17).

- Sakar Healthcare expects strong revenue growth driven by oncology product commercialization and marketing authorizations in EU and emerging markets from FY 2027 onwards. - FY 2026 revenue guidance is INR 280 crores, implying substantial growth over the previous year, with a majority of incremental sales expected in Q4. - EBITDA margins expected to normalize to around 25% after temporary dips due to one-time business development and registration expenses. - Oncology share in sales has doubled and is expected to improve margins and EBITDA as bulk business ramps up. - Working capital will grow with sales but efficiency improvements are expected to maintain stable working capital cycles. - CapEx for FY 2026 is largely complete; FY 2027 CapEx expected to be minimal and maintenance-only. - Overall, PAT grew 27.8% year-on-year in H1 FY 2026, with expectations of further earnings growth linked to export scale-up and oncology business ramp-up.

- Current capex requirement is nil; existing infrastructure supports projected growth (Page 17). - Recent capex includes approximately INR 27 crores, of which around INR 10 crores has been spent and INR 17 crores remain in capital work in progress (Page 10). - INR 27 crores includes some capacity expansion and modifications, primarily on the oncology side (Page 8). - No significant capex expected in FY 2027 except for maintenance-related spend (Page 10). - Working capital will increase in line with sales growth, but Days of Working Capital are expected to remain stable (Page 17). - No planned strategic capital investments mentioned beyond current oncology plant expansions and maintenance (Page 8, 17).

- There is no indication of any future capital expenditure (CapEx) requirement, as current infrastructure is expected to support growth targets (Bikramjit Ghosh, Page 17). - Working capital will increase in absolute terms in line with sales growth but will remain stable in terms of operating cycle days; no extraordinary working capital increase anticipated beyond normal growth scaling (Page 17). - No mention of plans for new fundraising via equity or debt in the transcript. - CapEx for FY 2026 and FY 2027 is limited, with INR 27 crores expected mainly toward oncology plant modifications; no additional major CapEx or fundraising anticipated (Page 10). - The company also notes no expected CapEx in FY 2027 except maintenance, implying no planned new fundraise for that purpose (Page 10).

- Sakar Healthcare has over 50+ agreements in oncology covering more than 250 SKUs/molecules. - Business plan includes contracts worth approximately INR 452 crores with overseas partners like Accord and Torrent. - Over 200 dossiers have been shared with partners; 80 dossiers have been filed, and 11 marketing authorizations (MAs) have been received. - Expecting 200+ MAs to benefit from commercialization starting FY 2027. - The total planned dossiers exceed 250, with an estimated 100 marketing authorizations expected after a 20% deduction. - Pending orders include dossiers in various stages of filing and approval across 48 countries, covering markets in Africa, Asia, Europe, UK, Latin America, MENA, and Oceania. - Initial purchase orders have started post-receipt of some MAs, with exports targeted from Q4 FY 2026.